X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Week in Review: The latest from PhRMA

By Priscilla VanderVeer  |    April 29, 2016
Fact Check Friday – When it comes to communications between with payers, biopharmaceutical companies are often constrained in sharing safety and efficacy information about medicines in development.  ...   Read More

Getting TTIP right, not rushed

By Jonathan Kimball  |    April 29, 2016
I had an opportunity to participate in the Stakeholders’ Event at the13th round of the Transatlantic Trade and Investment Partnership (TTIP) negotiations that took place in New York City earlier this...   Read More

Fact Check Friday: Biopharmaceutical company communications with payers

By Andrew Powaleny  |    April 29, 2016
Today, we’re examining how and what biopharmaceutical companies communicate with payers about a medicine prior to its approval by the U.S. Food and Drug Administration (FDA). MYTH:...   Read More

340B Spotlight: Despite access to discounts, many 340B hospitals fail to comply with ACA charity care requirements

By Rebecca Davison  |    April 28, 2016
Late last year, we highlighted a study published in in the New England Journal of Medicine that found many nonprofit hospitals were not complying with the charity care requirements laid out in the ...   Read More

Coming soon: Clinical Trials Awareness Week, May 2-6

By Andrew Powaleny  |    April 28, 2016
Clinical trials are the most effective way to find new, innovative treatments for illnesses patients may face. But misconceptions and lack of awareness about this important research often keep people...   Read More

New Research: Access and quality implications of CMS proposed Part B model

By Kelsey Lang  |    April 27, 2016
In recent weeks, providers and stakeholders across the health care system have raised concerns that the Part B Drug Payment Model proposed by the Centers for Medicare & Medicaid Services (CMS) lacks...   Read More

World IP Day: Celebrating the protections that allow innovation to thrive

By Mark Grayson  |    April 26, 2016
Today is World Intellectual Property Day, a celebration across the globe of the protections that allow creativity, risk-taking and innovation to thrive. America has long been the world’s innovation...   Read More

Medicare Monday: One-size-fits-all treatments are wrong for patients

By Allyson Funk  |    April 25, 2016
The government is proposing dramatic changes to Medicare Part B, including possible cuts to physician reimbursement for many innovative treatments based on the government’s decisions about which...   Read More

CSRxP proposals would undermine competitive market, harm patients and innovation

By Robert Zirkelbach  |    April 25, 2016
These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and...   Read More

ITIF report shows how Canada’s IP system is falling behind

By Mark Grayson  |    April 20, 2016
Over the last two and a half decades the world’s life expectancy has grown from 65 to 71 years. This life-changing advance is due in no small part to the creation of new drugs, therapies and...   Read More

New Avalere study: Health plan formularies continue to suggest bias against individuals with certain health conditions

By Karyn Schwartz  |    April 19, 2016
Despite warnings from the Centers for Medicare & Medicaid Services (CMS) that requiring high cost sharing for all or most medications to treat a condition may be discriminatory, new data from Avalere...   Read More

Medicare Monday: Provider consolidation drives up costs for patients and government

By Kelsey Lang  |    April 18, 2016
Two recent studies add to a growing body of research on how consolidation is driving up treatment costs. More and more cancer treatments are being administered at hospital outpatient facilities...   Read More

Matt and Jamie share their stories in new “From Hope to Cures” ads

By Ieva M. Augstums  |    April 18, 2016
For Matt, today is a great day to be alive. And if you ask him why today is possible for him and why tomorrow is possible, too, he will tell you: Innovative medicines saved his life. When he was...   Read More

Week in Review: The latest from PhRMA

By Priscilla VanderVeer  |    April 15, 2016
Competition works for pricing – Despite misleading claims to the contrary, a new report from IMS Institute for Healthcare Informatics found that net prices for brand medicines increased just 2.8...   Read More

New report confirms competitive market works; Net prices for medicines increased just 2.8 percent in 2015

By Holly Campbell  |    April 14, 2016
Despite misleading claims made about spending on new innovative treatments and cures, another report confirms how the competitive biopharmaceutical market works to control costs. Net prices for brand...   Read More

India denies patent on novel HIV/AIDS medicine

By Mark Grayson  |    April 14, 2016
In 2014, several months after Prime Minister Modi took office, he announced an ambitious initiative called “Make in India.” The goal was to encourage foreign and domestic companies to manufacture...   Read More

Targeting the immune system, not the tumor

By Andrew Powaleny  |    April 14, 2016
One of the most exciting areas of cancer research today is immuno-oncology. Immuno-oncology is based on the concept of harnessing the body’s own immune system to fight cancer, and while it’s an...   Read More

New Study: Patient cost sharing rising as plans push more costs to patients through deductibles, coinsurance

By Karyn Schwartz  |    April 13, 2016
New data show changes in how insurers structure health insurance benefits have made out-of-pocket costs harder for patients to budget for or predict. A Kaiser Family Foundation analysis released this...   Read More

Clinical Trials Q&A: Examining clinical trial design

By Jocelyn Ulrich  |    April 12, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

FDA issues draft biosimilars labeling guidance

By Andrew Powaleny  |    April 12, 2016
Labeling is an important aspect of the U.S. Food and Drug Administration (FDA) prescription drug approval process. FDA-approved prescription drug labeling is the most authoritative mechanism for...   Read More

Celebrating tremendous advances in HIV/AIDS on National Youth HIV/AIDS Awareness Day

By Hannah Mooney Mack  |    April 11, 2016
Yesterday was National Youth HIV/AIDS Awareness Day, an opportunity to educate on the impact of HIV and AIDS and to recognize advances in science that have brought hope to Americans. Thankfully, for...   Read More

Medicare Monday: Why Average Sales Price works

By Allyson Funk  |    April 11, 2016
With proposed changes to Medicare Part B and claims about how the program works, let’s take a look at what ASP is and how it works for Medicare providers and patients alike. What is Average Sales...   Read More

A voice for patients

By Guest Contributor  |    April 11, 2016
Dr. Michael Rosenblatt, Executive Vice President and Chief Medical Officer - Merck  I didn’t grow up thinking I wanted to become a chief medical officer (CMO), but at a young age, my love of science...   Read More

Week in review: The latest from PhRMA

By Priscilla VanderVeer  |    April 8, 2016
11 years of PPA – This week, we celebrated the 11th anniversary of the Partnership for Prescription Assistance (PPA) by launching a mobile app.  The new app will offer a single point of access to...   Read More

IP protections found to be critical to life-science innovation and investment

By Jay Taylor  |    April 7, 2016
A new report by the Information Technology and Innovation Foundation (ITIF) has found intellectual property (IP) protections to be crucial to stimulating risk-taking and innovation. The study, How...   Read More

Phased-in approach offers best hope for FDA’s proposed quality metrics program

By Camille Jackson  |    April 7, 2016
In July 2015, the U.S. Food and Drug Administration (FDA) issued draft guidance for industry requiring manufacturers to provide certain manufacturing data on an annual basis. The FDA’s Center for...   Read More

Dangers of drug importation: A case of counterfeit cancer drugs

By Holly Campbell  |    April 7, 2016
Counterfeit drug trafficking is a multibillion dollar business that threatens the health and well-being of patients. The World Health Organization estimates 10 percent of medicines worldwide are...   Read More

PPA connects nearly 10 million people; Celebrates 11th anniversary and launches mobile app

By Ieva M. Augstums  |    April 5, 2016
Today, the Partnership for Prescription Assistance (PPA) celebrates 11 years of helping people who are struggling with affordable access to their medicines at the pharmacy. In just over a decade, the...   Read More

Medicare Monday: A guide to MedPAC’s Part D vote this week

By Allyson Funk  |    April 4, 2016
The Medicare Payment Advisory Commission (MedPAC) is an independent congressional agency that advises Congress on issues related to the Medicare program, including payment, access to and quality of...   Read More

How to get value assessment frameworks right

By Holly Campbell  |    April 1, 2016
As the U.S. health care market evolves toward a system that better recognizes and rewards value, we face a pressing need to develop tools and solutions to empower informed patient-physician...   Read More

Week in Review: The latest from PhRMA

By Priscilla VanderVeer  |    April 1, 2016
Discriminatory effect of insurance plan structure – New research from Harvard’s Center for Health Law and Policy Innovation (CHLPI) shows evidence that some insurance plans are designed to discourage...   Read More

The tradeoffs: Personalized treatment vs. one-size-fits-all standards

By Allyson Funk  |    April 1, 2016
What would happen if instead of a personalized treatment plan your doctor used a one-size-fits-all standard of care? A recent government proposal to change Medicare Part B could create barriers to...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."